Legend Biotech (LEGN) Other Accumulated Expenses (2024 - 2025)
Legend Biotech's (LEGN) quarterly Other Accumulated Expenses came in at $1.0 million in Q4 2025, up 100.0% YoY from $500000.0 in Q4 2024, and little changed on a QoQ basis from $1.0 million in Q3 2025.
Legend Biotech (LEGN) Other Accumulated Expenses (2024 - 2025) Analysis & Trends
Legend Biotech (LEGN) has 2 years of Other Accumulated Expenses data on file, last reported at $1.0 million in Q4 2025.
- Quarterly Other Accumulated Expenses rose 100.0% year-over-year to $1.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $1.0 million (up 100.0% YoY) and the FY2025 annual result came in at $1.0 million, up 100.0% from the prior year.
- Other Accumulated Expenses held at $1.0 million in Q4 2025, from $1.0 million in the prior quarter.
- In the past five years, Other Accumulated Expenses ranged from a high of $1.0 million in Q3 2025 to a low of $500000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Legend Biotech | 3.95 Bn | 3.27 Bn | 251.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.00 Mn |
| Sep 30, 2025 | 1.00 Mn |
| Dec 31, 2024 | 500,000.00 |